Analyst Group Comment on Pharma Equity Group’s New Execution Strategy

Pharma Equity Group (“PEG” or “the Company”) announced on Friday, December the 13th, the board of directors’ decision on a new execution strategy and prioritization of clinical areas regarding the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex”).

Länk till analysen i sin helhet: https://analystgroup.se/kommentarer/comment-on-pharma-equity-groups-new-execution-strategy/